Non-small Cell Lung Cancer as a Chronic Disease - A Prospective Study from the Czech TULUNG Registry
| Authors | |
|---|---|
| Year of publication | 2020 |
| Type | Article in Periodical |
| Magazine / Source | In vivo |
| MU Faculty or unit | |
| Citation | |
| Web | http://dx.doi.org/10.21873/invivo.11783 |
| Doi | http://dx.doi.org/10.21873/invivo.11783 |
| Keywords | Non-small cell lung cancer; 2-year survival; modern-era treatment; personalized treatment; chronic disease |
| Attached files | |
| Description | Aim: To compare survival outcomes in patients with non-small cell lung cancer (NSCLC) treated with modern-era drugs (antifolates, antiangiogenics, tyrosine kinase and anaplastic lymphoma kinase inhibitors, immunotherapy) with treatment initiation in 2011-12 and 2015-16, respectively. Patients and Methods: Prospective data from Czech TULUNG Registry (960 patients from 2011-12 and 512 patients from 2015-16) were analyzed. Kaplan-Meier analysis was used to estimate overall survival (OS) and progression free survival (PFS); Cox proportional hazards model to assess factors associated with 2-year survival. Results: Survival at 2 years was more frequent in cohort 2015-16 compared to cohort 201112 (43.2% vs. 24% for adenocarcinoma; p<0.001 and 28.7% vs. 11.8% for squamous-cell lung carcinoma; p=0.002). Assignment to cohort 2015-16 and treatment multilinearity (two or more lines in sequence) were associated with higher probability of 2-year survival (hazard ratio=0.666 and hazard ratio=0 .597 ; p<0.001). Comparison of 2-year survivors from both cohorts showed no differences. Conclusion: Survival at 2 years probability in stage IIIB-IV NSCLC doubled between 2011-12 and 2015-16; advanced-stage NSCLC may be considered a chronic disease in a large proportion of patients. |